Tagged Articles

Avandia 216 articles

Common drugs that doctors refuse to take

Just because a medication is approved by the Food and Drug Administration (FDA) does not mean it is safe. In fact, many drugs have been linked to concerning side effects. That’s why it is important for patients to weigh the risks and benefits of all drugs before taking them, including seemingly innocuous over-the-counter medicines. Men’s Health magazine compiled a list of medications that doctors said they wouldn’t take themselves. If you or someone you love is taking any of these, it might be time to discuss your risk with a doctor. Pseudoephedrine – The decongestant that is used to manufacture ... Read More

Long-term pancreatic cancer risks with class of type 2 diabetes drugs still unknown

Drugs in a class of Type 2 diabetes medications known as DPP-4 inhibitors may not increase the short-term risk of pancreatic cancer, but the long-term risks are still unknown, according to a new study published in the journal Diabetes, Obesity and Metabolism. The study was conducted by researchers with the University of North Carolina (UNC) Gillings School of Global Public Health and the UNC School of medicine, and focused on pancreatic cancer risks with DPP-4 inhibitors such as Januvia and Janumet (sitagliptin), and Tradjenta (linagliptin). DPP-4 inhibitors were first marketed in the United States in 2006 and have since become ... Read More

Controversial analysis suggests Actos may help protect users from dementia

The type 2 diabetes drug Actos could help ward off dementia, a new analysis has found. However, researcher say more analysis is needed as well as adverse side effects addressed before the medication can be recommended as a preventative measure. The analysis involved data from Germany’s biggest public health insurer, which included about 146,000 patients aged 60 or older. The patients were tracked from 2004 to 2010, during which time about 14,000 of them developed dementia. When prescriptions for Actos were factored into the analysis, researchers found that patients taking Actos had about a 6 percent decline in the likelihood ... Read More

GSK pays $22 million to settle fraudulent marketing claims in West Virginia

GlaxoSmithKline (GSK) has agreed to pay $22 million to settle claims that the pharmaceutical company used illegal tactics to peddle its diabetes drugs. The settlement is one of the largest in West Virginia history, said Attorney General Patrick Morrisey. About $10.6 million will go to the state’s Public Employees Insurance Agency and $3.7 million to the Department of Health and Human Services’ Medicaid program. About $3.1 million will go to the attorney general’s Consumer Protection Fund and the remaining $4.6 million will be used to cover attorney’s fees and expenses. Morrisey, on behalf of West Virginia, argued that GSK failed ... Read More

GSK revamps marketing efforts following record settlement over illegal promotion of drugs

GlaxoSmithKline (GSK) says it will hire doctors to market its drugs to the medical community in an effort to mend its tarnished reputation following a $3 billion fraud settlement over questionable marketing practices. Since 2012, when GSK was accused of illegally promoting its antidepressants Paxil and Wellbutrin and failing to report safety data on its blockbuster diabetes drug Avandia, the drug company has been reforming its marketing efforts to provide more transparency. “We’ll continue to disseminate this very important information on drug benefits and risks, but we’re just not going to do that by hiring external speakers. We want to ... Read More

FDA approves new type 2 diabetes medication Farxiga

A new drug has been approved by the Food and Drug Administration (FDA) to help regulate blood sugar in patients with type 2 diabetes. Farxiga, developed by AstraZeneca and Bristol-Myers Squibb, has been available in Europe under the name Forxiga. U.S. drug regulators rejected the drug last year because of bladder cancer, heart disease and liver toxicity concerns. Farxiga is the second in a class of drugs known as SGLT2 inhibitors to be approved in the United States. Johnson & Johnson’s Invokana was approved earlier this year. Other drugmakers, including Boehringer Ingelheim, are also developing SGLT2 inhibitors. Drugs in this class ... Read More

Could your diabetes medication cause cancer?

Type 2 diabetes is a chronic condition that occurs when the body does not produce enough insulin to regulate glucose – or sugar – levels in the blood. If left uncontrolled, diabetes can lead to serious health complications including cardiovascular disease, kidney disease, dementia, amputations due to neuropathy, and blindness. People who are overweight and do not exercise regularly are at greater risk of developing type 2 diabetes. Many require medications to keep their blood sugar levels in check. These medications help millions of people manage their disease, but for some, there is a price – dangerous side effects. The warning ... Read More

FDA requests more data on diabetes drug candidate combining Invokana with metformin

The Food and Drug Administration (FDA) wants more clinical trial data on Janssen’s new type 2 diabetes treatment that combines the recently approved Invokana (canagliflozin) with the widely used metformin, before it will decide whether to approve the new combination therapy. The agency requested more information comparing the twice-daily combination pill with the once-daily canagliflozin. Janssen, a Johnson & Johnson company, says it has the data the agency needs from its comprehensive Phase 3 clinical development program for the drug. Canagliflozin was approved by the FDA in March 2013. It is the first approved drug in a new class of ... Read More

FDA panel recommends approval of new type 2 diabetes drug dapagliflozin

A Food and Drug Administration (FDA) advisory panel has voted to recommend the approval of a new type of type 2 diabetes medication two years after it was rejected by regulators based on concerns that it could increase the risk of cancer and cardiovascular events. Dapagliflozin, from Bristol-Myers Squibb and AstraZeneca, is a once-daily pill in a new class of diabetes medications known as SGLT-2 inhibitors. The FDA rejected the drug in January 2012, saying it needed more data to asses breast and bladder cancer concerns as well as heart risks. The drug companies resubmitted the application with several new ... Read More

Studies look at cancer risk, prevention with type 2 diabetes medications

A type of diabetes medications known as insulin sensitizers may reduce the risk of cancer by a third in women who used the drugs, a new study suggests. Insulin sensitizers include the commonly prescribed drug metformin as well as Avandia, known generically as rosiglitazone, and Actos, known generically as pioglitazone. The new study claims these insulin sensitizers were better at preventing cancer in women than diabetes drugs known as insulin secretagogues such as glyburide, glipizide and glimepiride. Type 2 diabetics are already 30 to 50 times more likely to develop cancer than those without the metabolic disorder. Women with diabetes ... Read More